Related Experiment Videos
Pharmacokinetics of a new inotropic catecholamine in dog plasma using solid phase extraction technology
1Schering Research, Miami, Fl. 33169.
Research Communications in Chemical Pathology and Pharmacology
|March 1, 1988
Summary
Pharmacokinetics of the novel catecholamine N-[2-(3,4-dihydroxyphenyl)-ethyl]-1-methyl-3-(3-carbomylphenyl)-pr opylamine HCL (KM-13) were studied in dogs. The drug exhibited a terminal elimination half-life of approximately 20 minutes.
Area of Science:
- Pharmacology
- Drug Metabolism
- Analytical Chemistry
Background:
- Novel synthetic catecholamines require thorough pharmacokinetic evaluation.
- Understanding drug disposition is crucial for therapeutic development.
Purpose of the Study:
- To characterize the pharmacokinetics of KM-13 in a canine model.
- To establish a sensitive analytical method for KM-13 quantification.
Main Methods:
- Intravenous administration of KM-13 (50 and 100 micrograms/kg) to dogs.
- Plasma extraction using Bond-Elut CN columns.
- Quantification by High-Performance Liquid Chromatography (HPLC) with electrochemical detection.
Main Results:
- Plasma concentration-time data fitted a bi-exponential model.
- Terminal elimination half-life was determined to be approximately 20 minutes.
- The analytical method demonstrated a sensitivity limit of 2 ng/ml.
Conclusions:
- KM-13 exhibits rapid elimination in dogs.
- The developed HPLC method is suitable for pharmacokinetic studies of synthetic catecholamines.